Scholarlink

<p>Homozygous deletions of cyclin-dependent kinase inhibitor 2&#xa0;A/B (<i>CDKN2A/B)</i> are recognized as poor prognostic markers in newly diagnosed IDH-mutant astrocytomas. However, a standardized definition of <i>CDKN2A/B</i> homozygous deletion has not yet been established. Furthermore, the prognostic significance of <i>CDKN2A/B</i> homozygous and hemizygous deletions at recurrence remains unclear. In this study, we investigated the prognostic impact of <i>CDKN2A/B</i> homozygous and hemizygous deletions in patients with recurrent IDH-mutant astrocytomas. We conducted a retrospective review of 32 patients treated at our institution between January 2006 and March 2023. <i>CDKN2A/B</i> homozygous and hemizygous deletions were defined as relative <i>CDKN2A/B</i> copy numbers of &lt; 0.4 and &lt; 0.7, respectively, as determined by multiplex ligation-dependent probe amplification. Univariate analysis demonstrated that both homozygous and hemizygous deletions at first recurrence were associated with shorter post-recurrence survival. Multivariable analysis identified both deletion types and histological grade at first recurrence as independent prognostic factors. Risk stratification based on histological grade and <i>CDKN2A/B</i> status effectively predicted survival outcomes following recurrence. In conclusion, <i>CDKN2A/B</i> status, alongside histological grading, represents an independent prognostic indicator in recurrent IDH-mutant astrocytoma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CDKN2A/B status and histological grade independently predict post-recurrence survival in recurrent IDH-mutant astrocytoma

  • 期刊论文

  • 发表日期：

    2026年5月21日

查看全文
  • Shota Yamashita,
  • Masayuki Kanamori,
  • Yoshiteru Shimoda,
  • Yoshinari Osada,
  • Mika Watanabe,
  • Rei Umezawa,
  • Keiichi Jingu,
  • Ichiyo Shibahara,
  • Ryuta Saito,
  • Yukihiko Sonoda,
  • Toshihiro Kumabe,
  • Hidenori Endo

摘要

Homozygous deletions of cyclin-dependent kinase inhibitor 2 A/B (CDKN2A/B) are recognized as poor prognostic markers in newly diagnosed IDH-mutant astrocytomas. However, a standardized definition of CDKN2A/B homozygous deletion has not yet been established. Furthermore, the prognostic significance of CDKN2A/B homozygous and hemizygous deletions at recurrence remains unclear. In this study, we investigated the prognostic impact of CDKN2A/B homozygous and hemizygous deletions in patients with recurrent IDH-mutant astrocytomas. We conducted a retrospective review of 32 patients treated at our institution between January 2006 and March 2023. CDKN2A/B homozygous and hemizygous deletions were defined as relative CDKN2A/B copy numbers of < 0.4 and < 0.7, respectively, as determined by multiplex ligation-dependent probe amplification. Univariate analysis demonstrated that both homozygous and hemizygous deletions at first recurrence were associated with shorter post-recurrence survival. Multivariable analysis identified both deletion types and histological grade at first recurrence as independent prognostic factors. Risk stratification based on histological grade and CDKN2A/B status effectively predicted survival outcomes following recurrence. In conclusion, CDKN2A/B status, alongside histological grading, represents an independent prognostic indicator in recurrent IDH-mutant astrocytoma.